Cyclerion Therapeutics (NASDAQ:CYCN) Trading Down 5.5% – Time to Sell?

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s share price traded down 5.5% on Thursday . The stock traded as low as $1.3601 and last traded at $1.37. 71,574 shares were traded during mid-day trading, a decline of 98% from the average session volume of 4,501,084 shares. The stock had previously closed at $1.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Cyclerion Therapeutics Price Performance

The firm has a market cap of $5.38 million, a PE ratio of -1.83 and a beta of 0.96. The company’s 50 day moving average price is $1.50 and its 200 day moving average price is $2.07.

Cyclerion Therapeutics (NASDAQ:CYCN) last released its earnings results on Thursday, October 30th. The company reported ($0.30) earnings per share (EPS) for the quarter. Cyclerion Therapeutics had a negative return on equity of 24.61% and a negative net margin of 77.02%.The business had revenue of $0.88 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP purchased a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. Institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.